NEWTOWN, Pa., & PENNINGTON, N.J.--(BUSINESS WIRE)--Onconova Therapeutics, Inc. announced two advances in the clinical development of ESTYBON (rigosertib, ON 01910.Na) in presentations at the annual meeting of the American Society of Clinical Oncology (ASCO), June 3-7, 2011, in Chicago, Illinois. Based on the positive trial results presented at the meeting, Onconova also announced the initiation of a Phase II/III study for pancreatic cancer.
